October 17th 2024
During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Whole-Genome Sequencing Identifies Actionable Mutations in HCC
January 17th 2014A research team at Cold Spring Harbor Laboratory in New York has succeeded in identifying the most common genetically altered genes and the major oncogenic drivers in hepatitis B virus-associated hepatocellular carcinoma (HCC).
Read More
Treating Renal Cell Carcinoma in 2013
January 6th 2014Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma (RCC). The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.
Read More
AGS-003 Activates Promising Immune Response in mRCC
November 18th 2013AGS-003, an investigational autologous dendritic cell vaccine, successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma (mRCC), according to an analysis presented at the 2013 Annual Meeting of the Society for Immunotherapy of Cancer.
Read More
Treatment of Advanced Renal Cell Carcinoma
October 26th 2013The treatment of advanced renal cell carcinoma (RCC) remains a major challenge for clinicians. However, according Daniel J. George, MD, the progress being made in understanding RCC tumor biology is already helping us to discover better, more effective treatments.
Read More
Pazopanib Poses Less Potential for Side Effects in RCC
October 7th 2013Though pazopanib and sunitinib are relatively similar in terms of efficacy in the treatment of advanced renal cell carcinoma, the former appears to cause fewer toxic side effects than the latter, suggesting that patients could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.
Read More
Evolution of Care in Advanced Kidney Cancer
September 19th 2013With seven targeted therapies approved for metastatic renal cell carcinoma (RCC), researchers and drug developers are now focusing on understanding the best way to sequence these therapies—and on identifying predictive biomarkers of response.
Read More